Acambis Plc Sample Contracts

Acambis Plc – Contract (June 28th, 2006)

Confidential treatment has been requested for certain portions of this exhibit. The copy filed herewith omits the information subject to the confidential treatment request. Omissions are designated as “*****”. A complete version of this exhibit has been filed separately with the Commission pursuant to an application for confidential treatment under Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.

Acambis Plc – [ACAMBIS PLC LETTERHEAD] (June 28th, 2006)

Following our review of the terms of appointment for Board members, the purpose of this letter (the “Agreement”) is formally to confirm the updated terms of your appointment as a Non-executive Director of Acambis (the “Company”).

Acambis Plc – Contract (June 28th, 2006)

Confidential treatment has been requested for certain portions of this exhibit. The copy filed herewith omits the information subject to the confidential treatment request. Omissions are designated as “ ***** “. A complete version of this exhibit has been filed separately with the Commission pursuant to an application for confidential treatment under Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.

Acambis Plc – Contract (June 28th, 2006)

Confidential treatment has been requested for certain portions of this exhibit. The copy filed herewith omits the information subject to the confidential treatment request. Omissions are designated as “*****”. A complete version of this exhibit has been filed separately with the Commission pursuant to an application for confidential treatment under Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.

Acambis Plc – [ACAMBIS PLC LETTERHEAD] (June 28th, 2006)

I am delighted that you have agreed to act as a Non-executive Director of the Board. The purpose of this letter (the Agreement) is formally to confirm the terms of your appointment as a Non-Executive Director of Acambis plc (the Company).

Acambis Plc – Contract (June 28th, 2006)

Confidential treatment has been requested for certain portions of this exhibit. The copy filed herewith omits the information subject to the confidential treatment request. Omissions are designated as “ ***** ”. A complete version of this exhibit has been filed separately with the Commission pursuant to an application for confidential treatment under Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.

Acambis Plc – Contract (June 28th, 2006)

Confidential treatment has been requested for certain portions of this exhibit. The copy filed herewith omits the information subject to the confidential treatment request. Omissions are designated as “*****”. A complete version of this exhibit has been filed separately with the Commission pursuant to an application for confidential treatment under Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.

Acambis Plc – Contract (June 28th, 2006)

Confidential treatment has been requested for certain portions of this exhibit. The copy filed herewith omits the information subject to the confidential treatment request. Omissions are designated as “ ***** ”. A complete version of this exhibit has been filed separately with the Commission pursuant to an application for confidential treatment under Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.

Acambis Plc – [ACAMBIS PLC LETTERHEAD] (June 28th, 2006)

Following our review of the terms of appointment for Board members, the purpose of this letter (the “Agreement”) is formally to confirm the updated terms of your appointment as a Non-executive Director of Acambis (the “Company”).

Acambis Plc – Contract (June 28th, 2006)

Confidential treatment has been requested for certain portions of this exhibit. The copy filed herewith omits the information subject to the confidential treatment request. Omissions are designated as “*****”. A complete version of this exhibit has been filed separately with the Commission pursuant to an application for confidential treatment under Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.

Acambis Plc – ASSET PURCHASE AGREEMENT by and between BioReliance Corporation and Acambis Inc. Dated May 6, 2005 (June 30th, 2005)

This Asset Purchase Agreement (“Agreement”) is dated May 6, 2005 (“Effective Date”), by and between Acambis Inc., a Delaware corporation with offices at 38 Sidney Street, Cambridge, MA 02139 (“Buyer”) and BioReliance Corporation, a wholly owned subsidiary of Invitrogen Corporation, a Delaware corporation, with offices at 14920 Broschart Road, Rockville, MD 20850 (“Seller”).

Acambis Plc – Contract (June 30th, 2005)

Confidential treatment has been requested for certain portions of this exhibit. The copy filed herewith omits the information subject to the confidential treatment request. Omissions are designated as “ ***** ”. A complete version of this exhibit has been filed separately with the Commission pursuant to an application for confidential treatment under Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.

Acambis Plc – Section A — Subcontract Form Subcontract No: MVA-2004-00001BXTR Subcontract between: Purchase Order No: To-Be-Determined Acambis Inc. Prime Contract No: To-Be-Determined (June 30th, 2005)

This Subcontract is entered into this 30th day of September, 2004, between Acambis Inc., 38 Sidney Street, Cambridge, MA 02139 (hereinafter “Contractor”) and Baxter Healthcare SA, Hertistrassse 2, CH 8304 Wallisellen, Switzerland (hereinafter “Subcontractor). This Subcontract is issued under the Prime Contract shown in the heading above, as executed between the Contractor and the United States Government, through the Department of Health and Human Services. In consideration of the mutual promises, covenants and agreements set forth herein, the parties agree that the Subcontractor shall furnish and deliver to the Contractor all the supplies and perform all the services set forth in this Subcontract, for the consideration stated herein. The rights and obligations of the parties to this Subcontract shall be subject to and governed by this Subcontract and other documents attached hereto or referenced herein.

Acambis Plc – Contract (June 30th, 2005)

Confidential treatment has been requested for certain portions of this exhibit. The copy filed herewith omits the information subject to the confidential treatment request. Omissions are designated as “ ***** ”. A complete version of this exhibit has been filed separately with the Commission pursuant to an application for confidential treatment under Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.

Acambis Plc – 8 July 2004 DIRECTOR’S SERVICE AGREEMENT between ACAMBIS plc - and - DAVID MUIR LAWRENCE Weil, Gotshal & Manges One South Place London EC2M 2WG Tel: +44 (0) 20 7903 1000 Fax: +44 (0) 20 7903 0990 www.weil.com (June 30th, 2005)
Acambis Plc – Contract (April 1st, 2005)

Confidential treatment has been requested for certain portions of this exhibit. The copy filed herewith omits the information subject to the confidential treatment request. Omissions are designated as “[*****]” or “*******”. A complete version of this exhibit has been filed separately with the Commission pursuant to an application for confidential treatment under Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.

Acambis Plc – Contract (April 1st, 2005)

Confidential treatment has been requested for certain portions of this exhibit. the copy filed herewith omits the information subject to the confidential treatment request. Omissions are designated as “[*****]” or “*****”. A complete version of this exhibit has been filed separately with the Commission pursuant to an application for confidential treatment under Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.

Acambis Plc – Contract (April 1st, 2005)

Confidential treatment has been requested for certain portions of this exhibit. The copy filed herewith omits the information subject to the confidential treatment request. Omissions are designated as “[*****]” or “*******”. A complete version of this exhibit has been filed separately with the Commission pursuant to an application for confidential treatment under Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.

Acambis Plc – Contract (April 1st, 2005)

Confidential treatment has been requested for certain portions of this exhibit. The copy filed herewith omits the information subject to the confidential treatment request. Omissions are designated as “[*****]” or “*******”. A complete version of this exhibit has been filed separately with the Commission pursuant to an application for confidential treatment under Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.

Acambis Plc – DISTRIBUTION, MANUFACTURING, AND LICENSE AGREEMENT (April 1st, 2005)

This Distribution, Manufacturing, and License Agreement is entered into at the date of countersignature (the “Effective Date”) by and between Acambis Research Limited, Peterhouse Technology Park, 100 Fulbourn Road, Cambridge CB1 9PT UK (“Acambis Research”) and Baxter Healthcare SA, having offices at Hertistrasse 2, CH-8304 Wallisellen, Switzerland (“BHSA”) and Baxter Healthcare Corporation, having offices at One Baxter Parkway, Deerfield, IL 60015 (“BHC”).

Acambis Plc – Contract (April 1st, 2005)

Confidential treatment has been requested for certain portions of this exhibit. The copy filed herewith omits the information subject to the confidential treatment request. Omissions are designated as “[*****]” or “*******”. A complete version of this exhibit has been filed separately with the Commission pursuant to an application for confidential treatment under Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.

Acambis Plc – Contract (April 1st, 2005)

Confidential treatment has been requested for certain portions of this exhibit. The copy filed herewith omits the information subject to the confidential treatment request. Omissions are designated as “[*****]” or “*******”. A complete version of this exhibit has been filed separately with the Commission pursuant to an application for confidential treatment under Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.

Acambis Plc – Contract (April 1st, 2005)

Confidential treatment has been requested for certain portions of this exhibit. The copy filed herewith omits the information subject to the confidential treatment request. Omissions are designated as “[*****]” or “*******”. A complete version of this exhibit has been filed separately with the Commission pursuant to an application for confidential treatment under Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.

Acambis Plc – Contract (April 1st, 2005)

Confidential treatment has been requested for certain portions of this exhibit. The copy filed herewith omits the information subject to the confidential treatment request. Omissions are designated as “[*****]” or “*******”. A complete version of this exhibit has been filed separately with the Commission pursuant to an application for confidential treatment under Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.

Acambis Plc – Contract (April 1st, 2005)

Confidential treatment has been requested for certain portions of this exhibit. The copy filed herewith omits the information subject to the confidential treatment request. Omissions are designated as “[*****]” or “*******”. A complete version of this exhibit has been filed separately with the Commission pursuant to an application for confidential treatment under Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.

Acambis Plc – Modification 0004 (April 1st, 2005)

Confidential treatment has been requested for certain portions of this exhibit. The copy filed herewith omits the information subject to the confidential treatment request. Omissions are designated as “[*****]” or “*******”. A complete version of this exhibit has been filed separately with the Commission pursuant to an application for confidential treatment under Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.

Acambis Plc – Contract (April 1st, 2005)

Confidential treatment has been requested for certain portions of this exhibit. The copy filed herewith omits the information subject to the confidential treatment request. Omissions are designated as “[*****]” or “*******”. A complete version of this exhibit has been filed separately with the Commission pursuant to an application for confidential treatment under Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.

Acambis Plc – Section A – Subcontract Form Subcontract between: Subcontract No: 200-2002-00010(BXTR) Acambis Inc. Prime Contract No: 200-2002-00004 Cambridge, MA 02139 Program Officer: [ **** ] AND Baxter Healthcare SA Baxter Healthcare Corporation Hertistrassse 2 One Baxter Parkway CH-8304 Wallisellen, Switzerland Deerfield, IL 60015 (April 1st, 2005)

This Subcontract is entered into this 14th day of November 2001, between Acambis Inc., 38 Sidney Street, Cambridge, MA 02139 (hereinafter “Contractor”) and Baxter Healthcare SA, Hertistrassse 2, CH-8304 Wallisellen, Switzerland (hereinafter “1st Subcontractor”) and Baxter Healthcare Corporation, One Baxter Parkway, Deerfield, IL 60015, (hereinafter “2nd Subcontractor”). The 1st Subcontractor and the 2nd Subcontractor together are hereinafter referred to as the “Subcontractors.” This Subcontract is issued under a Prime Contract executed between the Contractor and the United States Government, through the Department of Health and Human Services (Contract No. 200-2002-00004).

Acambis Plc – Contract (April 1st, 2005)

Confidential treatment has been requested for certain portions of this exhibit. The copy filed herewith omits the information subject to the confidential treatment request. Omissions are designated as “[*****]” or “*******”. A complete version of this exhibit has been filed separately with the Commission pursuant to an application for confidential treatment under Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.

Acambis Plc – Contract (April 1st, 2005)

Confidential treatment has been requested for certain portions of this exhibit. The copy filed herewith omits the information subject to the confidential treatment request. Omissions are designated as “[*****]” or “*******”. A complete version of this exhibit has been filed separately with the Commission pursuant to an application for confidential treatment under Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.

Acambis Plc – Back to Contents (April 1st, 2005)

Confidential treatment has been requested for certain portions of this exhibit. The copy filed herewith omits the information subject to the confidential treatment request. Omissions are designated as “[*****]” or “*****”. A complete version of this exhibit has been filed separately with the Commission pursuant to an application for confidential treatment under Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.

Acambis Plc – Contract (April 1st, 2005)

Confidential treatment has been requested for certain portions of this exhibit. The copy filed herewith omits the information subject to the confidential treatment request. Omissions are designated as “[*****]” or “*******”. A complete version of this exhibit has been filed separately with the Commission pursuant to an application for confidential treatment under Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.

Acambis Plc – Back to Contents (April 1st, 2005)

Confidential treatment has been requested for certain portions of this exhibit. The copy filed herewith omits the information subject to the confidential treatment request. Omissions are designated as “[*****]” or “*******”. A complete version of this exhibit has been filed separately with the Commission pursuant to an application for confidential treatment under Rule 24b–2 promulgated under the Securities Exchange Act of 1934, as amended.

Acambis Plc – Strictly Private and Confidential Mr Ross Graham c/o Acambis plc Peterhouse Technology Park 100 Fulbourn Road Cambridge CB1 9PT, UK Dear Ross Non-Executive Directorship (June 28th, 2004)

I am delighted that you have agreed to be appointed as a Non-Executive Director of the Board. The purpose of this letter (the "Agreement") is formally to confirm the terms of your appointment as a Non-Executive Director of Acambis (the "Company").

Acambis Plc – Contract (June 28th, 2004)

Confidential treatment has been requested for certain portions of this exhibit. The copy filed herewith omits the information subject to the confidential treatment request. Omissions are designated as " ***** ". A complete version of this exhibit has been filed separately with the Commission pursuant to an application for confidential treatment under Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.